9mw3011
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 10, 2023 (NCT06389942)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Transmembrane protease serine 6INHIBITOR
TMPRSS6 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06772766 | Phase 1 | Dec 30, 2024 | Mabwell |
| NCT06752746 | Phase 1 | Mar 21, 2024 | Mabwell |
| NCT06389942 | Phase 1 | Mar 10, 2023 | Mabwell |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mabwell | For profit | 3 | 3 | 1 | 2023 |
1 organizations
Page 1 / 1